Hutchmed, the original developer of Takeda’s Fruzaqla, has decided not to pursue an approval for the VEGFR inhibitor in ...

With a positive readout for its three-in-one hypertension drug, London-based George Medicines is one step closer to the ...

As a new deadly strain of mpox continues its global spread, Emergent BioSoultion's smallpox vaccine ACAM2000 has officially ...

Alnylam is circling the bases after walloping—in the words of chief medical officer Pushkal Garg M.D.—a “grand slam” with ...

After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide ...

Sanofi has suspended distribution of its two flu vaccines in China out of concern of waning potency. BioNTech's antibody-drug ...

A new appointee with more than two decades of comms experience will soon take the reins of Takeda’s worldwide brand strategy.

It’s been two years since the Inflation Reduction Act was passed, and while the law's Medicare-negotiated price cuts haven’t ...

Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered ...

Five years and nearly 50 episodes in, the CDC Foundation has given its “Contagious Conversations” podcast a makeover. | Five ...

In unveiling PfizerForAll, the drugmaker suggested that the new DTC platform will help fill a broad gap in the U.S.

Three years after launching Leqvio in the U.S., Novartis is still steadily advancing its blockbuster ambitions for the ...